Steelcase to Webcast First Quarter Conference Call
GRAND RAPIDS, Mich., June 10, 2020 (GLOBE NEWSWIRE) — Steelcase Inc. (NYSE: SCS) will webcast a discussion of its first […]
The RealReal Announces Proposed Offering of Convertible Senior Notes Due 2025
SAN FRANCISCO, June 10, 2020 (GLOBE NEWSWIRE) — The RealReal, Inc. (Nasdaq: REAL)—the world’s largest online marketplace for authenticated, cosigned […]
Verrica Pharmaceuticals Appoints Diem Nguyen, Ph.D., M.B.A., to its Board of Directors
– Global biopharmaceutical industry veteran brings significant commercial expertise and business acumen to help advance the Company’s medical dermatology portfolio […]
Daktronics, Inc. Announces Fiscal Year and Fourth Quarter 2020 Results
BROOKINGS, S.D., June 10, 2020 (GLOBE NEWSWIRE) — Daktronics, Inc. (NASDAQ – DAKT) today reported fiscal year and fourth quarter […]
Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020
SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative […]
G2 Goldfields Inc. Announces Private Placement Financing
TORONTO, June 10, 2020 (GLOBE NEWSWIRE) — G2 Goldfields Inc. (“G2” or the “Company“) (TSXV:GTWO) is pleased to announce that […]
NexTech’s InfernoAR Chosen as Virtual Events Platform Partner for Skybridge World Dubai
NEW YORK and TORONTO, June 10, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), […]
CB2 Insights Announces Delay in Filing Financials and Year End 2019 Financial Results Conference Call
TORONTO, June 10, 2020 (GLOBE NEWSWIRE) — CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), announces an update further […]
Fulcrum Therapeutics Completes $68.5 Million Private Placement
CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC) today announced the closing of a $68.5 million […]
RedHill Biopharma Submits COVID-19 Clinical Trial Application for Phase 2/3 Study with Opaganib
The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study of opaganib for severe COVID-19 patients is planned to be […]
